Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05814666 |
Recruitment Status :
Recruiting
First Posted : April 18, 2023
Last Update Posted : April 10, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HNSCC | Drug: Danvatirsen Drug: Pembrolizumab | Phase 2 |
This is a multicenter, open-label, Phase II, randomized, controlled study to determine the efficacy, safety, and other indicators of clinical and biological activity of the combination of danvatirsen and pembrolizumab as first-line treatment for R/M HNSCC.
After providing informed consent, patients will be assessed for eligibility during the screening phase of the study. All patients must be willing and able to provide a formalin fixed paraffin-embedded (FFPE) archival or fresh tumor sample collected during the screening period; a fresh biopsy is preferred if safe and feasible to obtain and consented to by the patient. Following the screening period, eligible patients will be randomized in a 2:1 ratio to danvatirsen + pembrolizumab or pembrolizumab monotherapy, respectively. Patients will receive treatment in 21-day cycles. Patients assigned to the pembrolizumab monotherapy arm will receive treatment until a criterion for discontinuation is met or a maximum of 24 months of treatment. Patients assigned to combination therapy will receive both treatments until a criterion for discontinuation is met or the patient has received a maximum of 24 months of treatment, after which they may remain on danvatirsen monotherapy.
Patients in both treatment arms will have radiologic tumor assessments every 6 weeks (±1 week), regardless of treatment delays, until objective disease progression, initiation of new anticancer treatment, death, withdrawal of consent, or end of study, whichever occurs first.
All patients who discontinue study treatment for any reason will have a safety follow-up visit 30 days (+7 days) after the last dose of study treatment and a follow-up for AEs 90 days (+7 days) after the last dose of pembrolizumab. Patients will be followed for survival at 12 week (±7 days) intervals until death or withdrawal of consent, whichever occurs first. Survival follow-up will continue until at least 15 months after the last patient is randomized in the study.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 81 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
Actual Study Start Date : | May 30, 2023 |
Estimated Primary Completion Date : | May 30, 2025 |
Estimated Study Completion Date : | May 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Danvatirsen plus pembrolizumab
Danvatirsen dosing: Week 1: Danvatirsen intravenously (IV) on Days 1, 3, and 5 Week 2 and subsequent weeks: Danvatirsen IV weekly Pembrolizumab dosing: Pembrolizumab every 3 weeks after the Danvatirsen dose. |
Drug: Danvatirsen
Danvatirsen is a STAT3 targeting drug.
Other Names:
Drug: Pembrolizumab Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
Other Name: Keytruda |
Active Comparator: Pembrolizumab
Pembrolizumab IV every 3 weeks after the Danvatirsen dose.
|
Drug: Pembrolizumab
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
Other Name: Keytruda |
- Confirmed ORR [ Time Frame: Up to 18 months ]Determine the ORR (Partial response [PR] + CR defined according to RECIST v1.1) as determined by the Investigator for the combination of danvatirsen and pembrolizumab compared with pembrolizumab alone
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 18 months ]Drug induced toxicities are assessed and graded according to Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0.
- DOR [ Time Frame: Up to 18months ]Duration of Response by RECIST v1.1
- DCR & CR Rate [ Time Frame: Up to 18months ]Disease control rate and complete response rate by RECIST v1.1
- ORR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]Overall response rate per RECIST v1.1 in tumors with CPS ≥ 20 and ≥ 50
- DOR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]Duration of response by RECIST v1.1 in tumors with CPS ≥50
- PFS [ Time Frame: Up to 18months ]Progression-free survival by RECIST v1.1, defined as the time from randomization to the first documentation of progressive disease (PD) or death from any cause, whichever comes first
- OS [ Time Frame: Up to 30months ]Overall survival, defined as time from randomization to death from any cause
- Maximum plasma concentration [ Time Frame: Up to 18 months ]Maximum concentration recorded [Cmax]of danvatirsen at defined timepoints in the combination regimen
- Trough concentration [ Time Frame: Up to 18 months ]Trough concentration [Ctrough] of danvatirsen at defined timepoints in the combination regimen
- Area under the plasma concentration-time curve [ Time Frame: Up to 18 months ]Area under the plasma concentration-time curve over the dosing interval [AUCtau] of danvatirsen at defined timepoints in the combination regimen
- Time to maximum plasma concentration [ Time Frame: Up to 18 months ]Time to maximum plasma concentration [Tmax]) after single and multiple doses at defined timepoints in the combination regimen
- Immunogenicity of danvatirsen [ Time Frame: Up to 18 months ]Anti-danvatirsen antibody titers at defined timepoints in the combination regimen
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must have given written informed consent (signed and dated).
- Aged ≥18 years at the time of informed consent.
- Recurrent/metastatic histologically or cytologically proven squamous cell carcinoma of the head and neck that is considered incurable by local therapy. Eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
- Presence of measurable tumor per RECIST v1.1 criteria.
- Detectable PD-L1 expression in tumor, defined as CPS ≥1 determined by a FDA or national regulatory agency of the country in which the patient resides.-approved test.
- Baseline fresh tumor biopsy or archival specimen.
- ECOG performance status of 0 or 1.
- Adequate organ function within 10 days of study treatment,
- Oxygen saturation on room air ≥92% by pulse oximetry.
- Females must be non-pregnant and non-lactating and either be postmenopausal or agree to adequate birth control.
- Males must be surgically sterile or agree to adequate birth control.
- Has an estimated life expectancy of at least 3 months.
- Has recovered from all complications or surgery and all toxicities of prior therapy
Exclusion Criteria:
- Prior therapy for metastatic HNSCC.
- Has disease suitable for local therapy with curative intent.
- Primary tumor of the nasopharynx.
- Has received prior therapy with an anti-programmed death 1 (PD-1), anti PD L1, or anti-programmed death-ligand-2 (PD-L2).
- Radiation therapy (or other non-systemic therapy) within 2 weeks of Day 1 of study treatment.
- Known autoimmune disease that has required systemic treatment
- Known immunodeficiency or receiving systemic steroid therapy that would be the equivalent of >10 mg prednisone daily
- Prior allogeneic tissue/solid organ transplant.
- Has significant cardiovascular disease
- Has received a live vaccine within 30 days
- Active infection requiring systemic antiviral or antimicrobial therapy
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- History of other malignancies
- Active HIV infection except patients who are currently stable on antiretroviral therapy for at least 4 weeks
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Treated or untreated parenchymal brain metastases or leptomeningeal disease.
- Treatment with another investigational drug, biological agent, or device within 1 month of screening, or 5 half-lives of investigational agent (if known), whichever is longer.
- Hypersensitivity to any component of danvatirsen or pembrolizumab.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05814666
Contact: Flamingo Therapeutics | +1 484 482 0007 | clinical@flamingotx.com |
United States, Arizona | |
The University of Arizona Cancer Center | Recruiting |
Tucson, Arizona, United States, 85719 | |
Contact: Study Coordinator | |
Contact 520-621-2999 | |
United States, California | |
University of California Irvine (UCI) | Recruiting |
Irvine, California, United States, 92617 | |
Contact: Clinical Research Manager 714-509-2643 | |
TMPN Hunt Cancer Care | Recruiting |
Torrance, California, United States, 90505 | |
Contact: Study Coordinator 310-750-3376 | |
University of California Los Angeles | Recruiting |
Westwood, California, United States, 90024 | |
Contact: Study Coordinator 310-794-2464 | |
United States, Colorado | |
University of Colorado Hospital (UCH) Anschutz Cancer Pavilion | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Study Coordinator | |
United States, Florida | |
Miami Cancer Institute | Recruiting |
Miami, Florida, United States, 33176 | |
Contact: Study Coordinator | |
Contact 786-527-8546 | |
United States, Kansas | |
AMR Kansas City Oncology | Recruiting |
Merriam, Kansas, United States, 66204 | |
Contact: Site Manager 913-386-7557 | |
University of Kansas Medical Center | Recruiting |
Westwood, Kansas, United States, 66205 | |
Contact: Project Manager 913-574-2854 | |
United States, Nevada | |
Comprehensive Cancer Centers of Nevada | Recruiting |
Las Vegas, Nevada, United States, 89169 | |
Contact: Site Manager 702-862-1100 | |
United States, New York | |
Mount Sinai | Recruiting |
New York, New York, United States, 10029 | |
Contact: Clinical Trials Manager 212-824-7860 | |
Stony Brook Cancer Center | Recruiting |
Stony Brook, New York, United States, 11794 | |
Contact: Research Nurse | |
Contact 631-216-2990 | |
United States, Ohio | |
The Christ Hospital Cancer Center | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
Contact: Operations Manager 513-585-1140 | |
University of Cincinnati Medical Center | Recruiting |
Cincinnati, Ohio, United States, 45229 | |
Contact: Study Coordinator | |
Contact 513-584-7703 | |
University Hospitals Cleveland | Recruiting |
Cleveland, Ohio, United States, 44106 | |
Contact: Study Coordinator | |
Contact 216-286-9469 | |
United States, South Carolina | |
Prisma Health Cancer Institute | Recruiting |
Greenville, South Carolina, United States, 29605 | |
Contact: Site Manager 864-522-2066 | |
Korea, Republic of | |
Gyeongsang National University Hospital | Recruiting |
Jinju, Korea, Republic of, 52727 | |
Contact: Study Coordinator | |
Contact 82-10-2858-4757 |
Responsible Party: | Flamingo Therapeutics NV |
ClinicalTrials.gov Identifier: | NCT05814666 |
Other Study ID Numbers: |
FLM-6774-201 |
First Posted: | April 18, 2023 Key Record Dates |
Last Update Posted: | April 10, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Squamous Cell Carcinoma of Head and Neck Carcinoma, Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Head and Neck Neoplasms |
Neoplasms by Site Pembrolizumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |